Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAPKEY
2024-514241-10-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Kaposi sarcoma (KS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Best Overall Response Rate (BORR) at 6 months and Best Overall Response Rate (BORR) at 24 months (Extension stage). Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on 2024-514241-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514241-10-00.